IBI3042 clinical trials
Also written IBI3042.
How each study uses IBI3042 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the IBI3042 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- IBI3042
- 2
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 1
Fortvita Biologics (USA)Inc. (1) · Hongwei Jiang (1) · Innovent Biologics (Suzhou) Co. Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test IBI3042.
- Feb 2027A Study of IBI3042 in Healthy Adult ParticipantsPhase 1 · Fortvita Biologics (USA)Inc.
- Mar 2027An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese ParticipantsPhase 1 · Hongwei Jiang
- Sep 2027IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsPhase 1 · Innovent Biologics (Suzhou) Co. Ltd.
Studies
Open first, then newest update. How each study uses IBI3042 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Study of IBI3042 in Healthy Adult ParticipantsNot yet recruitingPhase 1Fortvita Biologics (USA)Inc.NCT07842393Written as Investigational Drug: IBI3042
- IBI3042 Study in Healthy Participants and Overweight or Obese ParticipantsRecruitingPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT07793019Written as IBI3042
- An Exploratory Study of Single-Dose and Multiple-Doses IBI3042 in Healthy, Overweight, or Obese ParticipantsNot yet recruitingPhase 1Hongwei JiangNCT07802899Written as IBI3042